-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Pharmaceutical Guanlan
On June 2, the China Drug Clinical Trial Registration and Information Disclosure Platform showed that Zejing Pharmaceuticals launched a Phase 3 clinical trial of Jacketinib Hydrochloride Tablets for the treatment of severe alopecia areata.
Screenshot source: Chinadrugtrials
Alopecia areata is the second highest incidence of hair loss in the world.
At present, the existing treatment drugs and steroids do not provide meaningful improvement for many patients with alopecia areata, and they urgently need an effective treatment plan.
Just in April this year, Eli Lilly and Company and Incyte's JAK inhibitor baritinib achieved positive results in the second phase 3 clinical trial for the treatment of patients with severe alopecia areata.
Public information shows that Jacketinib hydrochloride tablets are new small-molecule JAK kinase inhibitor drugs independently developed by Zejing Pharmaceuticals with independent intellectual property rights, and belong to a class 1 new drug.
This time, Zejing Pharmaceutical initiated a multi-center, randomized, double-blind, placebo-controlled phase 3 clinical trial.
In addition to targeting alopecia areata, Zejing Pharmaceutical is also carrying out a number of clinical studies on Jacketinib hydrochloride tablets.
Note: The original text has been deleted
Reference materials:
[1] China Drug Clinical Trial Registration and Information Disclosure Platform.
